CLOSED
GET A PIECE OF ORTEK THERAPEUTICS
Setting a new standard for optimal oral health
Show more
REASONS TO INVEST
TEAM
Mitchell Goldberg • President
Read More
Steven Sablotsky • Director
Read More
Fred Confessore • Advisor
Read More
*Information provided by Research and Markets (source)
Overview
Seasoned pioneers in the oral care industry
Ortek has already conquered the expensive, time consuming and risky hurdles of commercializing our products. The internationally patented Ortek-ECD has been cleared by the FDA and is already used by hundreds of dentists in the US. The ECD utilizes breakthrough electronic conductance technology and does not use radiation. By painlessly touching a tooth’s surface, the ECD immediately and accurately helps dental professionals detect tiny cavities in our vulnerable back teeth; decay that is often missed by X-rays.
Ortek’s BasicBites soft chews are clinically shown to help maintain enamel health using nature inspired oral microbiome technology. Both products are designed to help solve a major public health burden by the early diagnosis of tooth decay and taking an innovative approach to supporting enamel health.
Tooth decay is the world’s most common chronic disease (source)
and detecting it early is critical to avoid the pain of more advanced cavities, root canals, infections and tooth loss. Ortek has developed two revolutionary products to help people take back control of their oral health: The Ortek-ECD and BasicBites.
An experienced and highly successful team leads Ortek. President and founder, Mitch Goldberg, has over 35 years of experience in the healthcare industry and was previously the co-founder, Executive VP and Director of Noven Pharmaceuticals, a two-person startup that became a highly profitable, publicly traded prescription drug company that was acquired for $428 million in cash. Goldberg is responsible for the clinical development, FDA clearance, commercial scale up, manufacturing and commercialization for the Ortek-ECD and for the commercialization of BasicBites. Ortek’s revolutionary technology is the result of its long-standing strategic alliance with The Research Foundation for The State University of New York and the world-renowned researchers in the Department of Oral Biology and Pathology at Stony Brook University School of Dental Medicine.
The Problem
Close to one-third of the world's population suffers from tooth decay
Close to one-third of the world's population suffers from tooth decay and X-rays often fail to detect certain prevalent cavities in time (source). An estimated 2.3 billion people worldwide suffer from tooth decay in their permanent teeth and more than 530 million children suffer from cavities in their baby teeth.1 According to the CDC, about one-fourth of young children, half of adolescents, and more than 90% of adults have experienced tooth decay (source).
1 CDC - Children’s Oral Health
Additionally, the back teeth (molars and premolars) are the sites most susceptible to cavities. These teeth have grooves, known as pits and fissures, that often trap cavity-causing bacteria (source). Dental X-rays and other methods often fail to detect cavities within the back teeth until there is advanced decay.2
The Solution
Game-changing Technology -
A remarkable advance in early cavity detection and an innovative microbiome approach to supporting enamel health
ECD
By painlessly measuring electrical conductance of enamel, the Ortek-ECD® can instantly detect cavities on the biting surfaces of the back teeth helping solve an everyday challenge for dental professionals. X-ray and other methods often miss early cavities on these extremely vulnerable surfaces until decay has advanced further into the tooth structure. The ECD is a small portable device that has a base unit with a digital display and a handpiece which utilizes disposable one-time use conductive stainless steel tips.
*The above is a computer-generated rendering of a functioning product that is currently available on the market.
For dentists and hygienists, this amazing point-of-care diagnostic tool enhances their dental practice by improving patient outcomes, retaining patients, and attracting new ones. The ECD is easy to use, painless, generates immediate and accurate results, and is extremely affordable, providing a new profit center for dental offices that can provide them a return on investment in just days.
*Study published in the Journal of Clinical Dentistry (J Clin Dent 2019;30:1-5)
Comparison of the Detection of Early Occlusal Caries in Extracted Human Permanent Molar Teeth by Electrical Conductance and Biopsy Means
Robi Chatterjee, Research Scientist; Ana Maria Acevedo, Full Professor and Research Scientist
Israel Kleinberg, Distinguished Professor, Director of Translational Oral Biology Stony Brook University, School of Dental Medicine Department of Oral Biology and Pathology, Division of Translational Oral Biology Stony Brook, NY, USA J Clin Dent. 2019 Jun,30 (2):1-5
Case Studies
First case study:
In this case, the patient had an obvious cavity on a section of their tooth (Site 1) and a slightly discolored or questionable spot (site 2). X-rays failed to detect any cavity for site 2 and visual examination was inconclusive, making the dentist's treatment decision very difficult.
Prior to initial preparation through the enamel layer, the ECD gave the following readings: site 1, 93 and site 2, 04. In this case, the ECD scores proved extremely reliable relative to the depth of the cavities. More importantly, the ECD was very effective in detecting a cavity that may have normally gone untreated.
Second case study:
In this case, two adjoining teeth displayed discoloration possibly due to staining. X-rays were taken and there was no sign of cavities. This case was a diagnostic challenge for the dentist.
Prior to initial preparation through the enamel layer, the ECD gave the following readings: 08 and 00. In this case, the ECD detected a cavity and the depth of the decay was over 2mm. The tooth with the 00 reading will be monitored, as the zero score by the ECD indicates that the stain or lesion did not extend through the enamel.
What Dental Professionals are Saying
Key opinion leaders Dr. Howard Glazer and Dr. Pamela Maragliano-Muniz recommend the Ortek-ECD.
*The above video was created and produced by the issuer prior to it determining to offer securities under Regulation CF. The discussion of investment return and image of ROI in the video applies to the issuer's customers and is not a guarantee of future performance or success.
*This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.
“The Ortek-ECD can pay for itself in just a few uses. No longer do we have to let our diagnosis of caries be a gut feeling. We can actually apply analytics.”
Joshua Austin, DDS, MAGD
Dental Economics, Pearls for your Practice
"I have used the ECD on numerous patients and it's extremely effective in detecting small cavitated lesions that may normally go untreated. The ECD scores are very reliable relative to the depth of the caries lesions."
Derek Zimbardi, DDS
Dentistry Today, Quick Technique
"I have used the ECD on over 200 patients and I have never had a false positive. It's an amazing device that should be incorporated into nearly every dental practice. The ECD dramatically helps my patients and it can pay for itself in no time. I was so impressed with Ortek's university based technologies that I purchased stock in the company."
Brian Rosen, DDS
"I have found the Ortek-ECD device to be one of my most useful go-to tools for the early detection of pit and fissure caries. It is easy to use and a great complement to an intraoral camera for patient communication and discussion regarding their oral health status."
Neville Hatfield, DMD, MBS
*These testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.
BasicBites
BasicBites is are delicious sugar free, candy-like, soft chews designed for people who suffer from dry mouth and great for those with a “sweet tooth”. Recommended by leading dental professionals, these soft chews contain Ortek’s revolutionary oral microbiome technology and are available in two mouth-watering flavors, chocolate and caramel. Just two delicious BasicBites per day have been clinically shown to help maintain enamel health. BasicBites work differently than other oral care products. Renowned university researchers cracked nature’s code for supporting enamel health by discovering beneficial bacteria in dental plaque. These friendly bacteria produce buffers instead of harmful acids. The arginine bicarbonate in BasicBites nurtures and activates these beneficial pH-raising bacteria. This healthy and balanced oral pH environment allows the calcium carbonate in BasicBites to support the fortification of the enamel. By harnessing the power of nature, multi-action BasicBites immediately neutralizes harmful sugar acids, enriches enamel, and helps maintain a balanced and healthy oral pH environment.
What Dental Professionals are Saying
*These testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.
The Market
The oral care market is massive and growing and our products directly address its unmet needs
The global dental services market was valued at $371.4 billion in 2020 and is expected to hit $698.8 billion by 2030 (source), while the worldwide dental equipment market was valued at $60.5 billion in 2019 and is predicted to reach $70.8 billion by 2024 (source). Globally, an estimated $298 billion is spent in direct costs associated with dental cavities, while an estimated $144 billion is spent on the indirect costs associated with dental cavities (source).
There’s a tremendous global opportunity for the ECD. With approximately 200,000 dentists in the US and nearly 1 million dentists in the world, capturing 25% market share of this large targeted audience could generate over 150 million in sales. Additionally, the ECD tips are disposable and for one time use which could lead to additional ongoing revenue streams (source, source).
The market for BasicBites is also vast. In 2020, the global oral care market was valued at $45 billion and is estimated to reach $53 billion by 2025 (source). In 2019, the worldwide functional food market had an estimated size of around $178 billion and is expected to reach around $268 billion by 2027 (source). Additionally, BasicBites are targeted for those individuals who suffer from dry mouth which is about one in four adults. The global market of dry mouth products was approximately $650 million in 2020 and projected to reach $825 million in 2027 (source).
We believe ECD and BasicBites are unlike any other products in the dental and oral care markets. The ECD does not use radiation and helps dentists diagnose cavities in our vulnerable back teeth at the earliest possible stage. X-rays and other methods often fail to detect early cavities in these susceptible sites until there is more advanced decay. By unlocking the power of the oral microbiome, BasicBites takes a new approach to oral care. The breakthrough prebiotic microbiome technology in BasicBites is based on decades of university research investigating how mixed oral bacterial communities naturally interact to help maintain enamel health.
Our Traction
Nationwide adoption from dental professionals and consumers
The Ortek-ECD and BasicBites technology were developed and tested at a leading US dental school. The ECD is FDA cleared and being used by hundreds of dentists throughout the US. In a published peer-reviewed clinical study, the ECD demonstrated 100% sensitivity and 93% specificity in detecting and diagnosing early cavities in back teeth.3 Ortek has obtained global patent protection for ECD in numerous key markets and has two patent-pending variants for BasicBites.
BasicBites has been on the market since 2014 and is clinically shown to support and maintain enamel health. Recently, we finalized a formulation for a new patent-pending line extension of BasicBites. Cumulative sales of BasicBites have reached over $1 million to date, all with a limited marketing budget only focused on educating dental professionals.
3 Study published in the Journal of Clinical Dentistry (J Clin Dent 2019;30:1-5)
Through our long-standing strategic alliance with The Research Foundation for The State University of New York, Ortek also has worldwide exclusive licenses for two patents that naturally rebalance the body’s skin microbiome to suppress body odor and combat drug-resistant bacteria. These patented technologies are intended for topical administration for a wide array of over-the-counter and prescription products and Ortek is seeking strategic partners to further develop and commercialize these cutting-edge technologies.
Why Invest
Together, we have the power to help millions optimize their oral health
Our vision for Ortek is to be a highly profitable global leader in the dental and oral care spaces, helping to alleviate a major global healthcare burden with our cutting-edge innovations. Our goal for the ECD is to have this breakthrough device in nearly every dental office throughout the world. For BasicBites, our mission is to target the huge dry mouth and consumer oral care markets across the US and the globe.
We are raising funds at this time so we can reach larger target audiences for the ECD and BasicBites. Our marketing programs will include social media, email, affiliate and influencer digital marketing strategies. Additionally, we will expand our professional print media, consumer and professional public relations campaigns, attendance at trade shows and further build our team of key opinion leaders. We will also leverage our existing professional and consumer database for repeat business, product referrals, and testimonials.
With the global dental services market expected to hit $698.8 billion by 2030 (source) and the global oral care market expected to reach $53 billion by 2025 (source), there is an ever-growing need for products like ours. And with tooth decay being the world’s most common chronic disease (source), Ortek has the power to truly make a difference. We’ve already conquered the expensive, time consuming and risky hurdles of commercializing our products. The Ortek-ECD is cleared by the FDA, patented internationally, and is now being successfully implemented by hundreds of dentists. BasicBites have been purchased by thousands of customers and we have only scratched the surface of the large dry mouth and oral care markets. We hope you will join us for this next phase of our growth, as we strive to truly make an impact improving oral health and create shareholder value.
Setting a new standard for optimal oral health – We are poised for growth
ABOUT
HEADQUARTERS
4 Expressway Plaza, Suite 206
Roslyn Heights, NY 11577
WEBSITE
View Site
TERMS
Ortek Therapeutics
Overview
PRICE PER SHARE
$1
DEADLINE
Sep. 7, 2022 at 6:59 AM UTC
VALUATION
$22.74M
FUNDING GOAL
$10K - $1.07M
Breakdown
MIN INVESTMENT
$250
MAX INVESTMENT
$25,000
MIN NUMBER OF SHARES OFFERED
10,000
MAX NUMBER OF SHARES OFFERED
1,070,000
OFFERING TYPE
Equity
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives and Bonuses*
Time-Based:
Friends and Family Early Birds
Invest within the first 7 days and receive an additional 20% bonus shares.
Super Early Bird Bonus
Invest within the first 15 days and receive an additional 15% bonus shares.
Early Bird Bonus
Invest within the first 30 days and receive an additional 10% bonus shares.
Amount-Based:
$250+ | 1st Perk
Invest $250+ and receive a onetime $5 off for a single bag of BasicBites.
$1,000+ | 2nd Perk
Invest 1,000 and receive 5% bonus shares
$2,500+ | 3rd Perk
Invest $2,500 and receive 10% bonus shares
$5,000+ | 4th Perk
Invest $5,000+ and receive two free bags of BasicBites and 15% bonus shares
$10,000+ | 5th Perk
Invest $10,000 and receive four free bags of BasicBites and 20% bonus shares
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Ortek Therapeutics, Inc will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
*Stacking perks only applies to the Owner's Bonus perk and Previous Backer perks. Time-based and Amount-based perks do not stack on top of each other, rather, the issuer will receive the greater of the two bonuses if they qualify for both.
Insider Investment Notice
Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.
Irregular Use of Proceeds
PRESS
ALL UPDATES
09.07.22
Thank You To Our New Investors!
On behalf of our leadership team, we thank you for your confidence and trust in making our StartEngine campaign a success. We will work relentlessly to grow our business.
Once we receive all of the investor contact information, we will happily send you your perks. If you have questions regarding your investment; inquiries can be sent to www.ortekinc.com/investor-contact
Thank you again!
Mitch Goldberg
President
Ortek Therapeutics, Inc.
09.06.22
Just Hours Left To Invest In Ortek
It's Not Too Late to Jump On Board our Mission to Disrupt the Multi-Billion Dollar Oral Care Market. We Hope You Come for the Ride, but You Better Hurry!
For those of you in our community who have already invested, we want to take this opportunity to thank you for your trust. For those considering an investment, please review our StartEngine campaign page link.
Key Reasons to Invest:
- Experienced and tested management
- The Ortek-ECD® detects very early tooth decay missed by X-rays
- The ECD has been cleared by the FDA and is patented in 20 countries
- Tooth decay is the world's most common disease
- Early detection of tooth decay spares individuals the pain and expense of advanced decay, root canals, infections and tooth loss
- BasicBites® contains our advanced oral microbiome technology
- Our commercialized products target multi-billion dollar markets
- Robust product pipeline
- New agreement just announced to develop Ortek's patented cutaneous microbiome body odor technology
We are raising funds at this time so we can reach, with greater frequency, massive target audiences for our game-changing Ortek-ECD®, our FDA cleared and globally patented early cavity detection device and BasicBites®, the soft chew that provides extra enamel support with our revolutionary microbiome technology. We also have new products in the pipeline and just announced a new development agreement to advance our cutaneous oral microbiome technology!
Ortek is not your typical med tech crowd-funded start-up. We already are selling two products that have received rave reviews from our growing customer base of thousands of consumers and dental professionals and we have only begun to tap into the tremendous potential of these products.
With a proven track record of success, our prospects have never been brighter.
Join us on our journey as We Redefine Oral Health!
Thank you again for your investment and interest in Ortek!
Mitch Goldberg
President
Ortek Therapeutics, Inc.
09.05.22
Just 1 Day Left to Invest in Ortek
Join us as We Redefine Oral Health!
Our equity crowdfunding campaign on StartEngine is ending in one day. If you have already invested in Ortek - A Special Thank You!
Still considering an investment? Please review our reasons to invest below:
New Corporate Milestone!
We are pleased to announce that Ortek has entered into an agreement to develop its patented cutaneous microbiome body odor technology with a company specializing in the research and commercialization of advanced microbial technologies. If successful, this development agreement could potentially lead to an exclusive sublicense agreement.
Veteran Proven Management —
Ortek's President and Director have a combined 75 years of healthcare experience. Mitch Goldberg and Steven Sablotsky were founders of Noven Pharmaceuticals. Noven was a two-person transdermal drug delivery startup specializing in women's healthcare and transmucosal dental technologies. Noven transformed into a fully integrated pharmaceutical company with over 600 employees, was a NASDAQ listed public company, and was eventually sold for $428 million in cash.*
FDA cleared Ortek-ECD® —
- An FDA Cleared Class II Medical Device
- Patented in 20 ountries
- Detects early biting surface tooth decay that X-rays often miss
- Provides a digital score based on decay progression into the dentin
- Does not utilize radiation
- Has been purchased by hundreds of dentists in the U.S.
- Named a Top 100 product by Dentistry Today
- Tooth decay is the world's most common chronic disease**
- Early detection of tooth decay spares individuals the pain and expense of advanced decay, root canals, infections and tooth loss
- The ECD is a very affordable and profitable new diagnostic tool for dental professionals
- The worldwide dental equipment market was valued at $60.5 billion in 2019 and is predicted to reach $70.8 billion by 2024***
BasicBites® —
- Contains our advanced oral microbiome technology
- Activates beneficial pH-raising oral bacteria
- Immediately neutralizes harmful sugar acids, supports remineralization and helps maintain a balanced and healthy oral pH environment
- BasicBites have over $1 million in cumulative sales
- Essential for the estimated one in four adults with dry mouth
- The global market of dry mouth products was approximately $650 million in 2020 and projected to reach $825 million in 2027****
- In 2020, the global oral care market was valued at $45 billion and is estimated to reach $53 billion by 2025*****
Robust Product Pipeline —
- BasicBites Synergy Plus™ for additional oral care, bone, cardiovascular and immunity support will be launched in Q4
- BasicBites Bedtime™ for additional oral care and sleep support will be launched soon
- Ortek has exclusive licenses for two patents that naturally rebalance the body’s skin microbiome to suppress body odor and combat drug-resistant bacteria
Join us on our journey as we grow and prosper by revolutionizing oral care.
*https://www.bizjournals.com/southflorida/stories/2009/08/24/daily71.html
**https://www.researchgate.net/publication/272725948_Dental_Caries_The_Most_Common_Disease_Worldwide_and_Preventive_Strategies
***https://www.bccresearch.com/market-research/healthcare/dental-markets-furniture-equipment-materials-supplies.html
****https://www.researchandmarkets.com/reports/5303834/xerostomia-dry-mouth-therapeutics-global
*****https://www.globenewswire.com/news-release/2020/07/21/2064748/0/en/The-oral-care-oral-hygiene-market-is-projected-to-reach-USD-53-3-billion-by-2025-from-USD-45-8-billion-in-2020-at-a-CAGR-of-3-1.html
09.04.22
Dental Professionals Endorse Ortek's Revolutionary Products - Learn Why
Howard Glazer, DDS, FAGD
Joshua Austin, DDS, MAGD
Derek Zimbardi, DDS
Neville Hatfield DMD MBS
"The ECD provides more bang for the buck than any comparable device and is surprisingly accurate with no second guessing about stained fissures. Use it during hygiene for one day, do the operative, and find out for yourself!"
Daniel J Poticny, DDS
"The Ortek ECD has been a boon to my practice. Patients immediately accept this wonderful addition to my diagnostic regimen. The ECD paid for itself easily within the first day or two!"
Michael D Stern, DDS, FAGD
BasicBites® – Unlocking the Power of the Oral Microbiome for Enamel Health
Sarah Clark, RDH, IPDH
Brooke Crouch, RDH
Just 2 days left!
These testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.
09.03.22
Ortek Announces Agreement to Develop its Microbiome Technology With Microbial Sciences Company
We are pleased to announce that Ortek has entered into an agreement to develop its cutaneous microbiome body odor patent with a company specializing in the research and commercialization of advanced microbial technologies. If successful, this development agreement could potentially lead to an exclusive sublicense agreement.
Through our long-standing strategic alliance with The Research Foundation for The State University of New York, Ortek has exclusive licenses for two patents that naturally rebalance the body’s skin microbiome to suppress body odor and combat drug-resistant bacteria. These patented technologies are intended for topical administration for a wide array of over-the-counter and prescription products. This agreement is specifically for the development of our microbiome body odor technology. The global deodorant market was valued at USD 73.15 billion in 2021 and is expected to reach USD 108.74 billion by 2029.* No additional terms can be released at this time.
Source:
*https://www.databridgemarketresearch.com/reports/global-deodorant-market
Disclaimer. There is no assurance that this development agreement will be successful and lead to commercialized products or a sublicense agreement. The development agreement can be terminated at any time by our partner.
09.02.22
Just 4 Days Left to Invest in Ortek
For those of you who've already invested, we thank you for putting your trust in us.
If you haven't invested yet, join us and let's disrupt the multi-billion dollar oral care industry together!
09.01.22
Still on the Fence? — Please Review Reasons to Invest
Closing in 5 Days — Invest Today
Experienced Management
Ortek's President and Director have a combined 75 years of healthcare experience. Mitch Goldberg and Steven Sablotsky were founders of Noven Pharmaceuticals. Noven was a two-person transdermal drug delivery startup specializing in women's healthcare and transmucosal dental technologies. Noven transformed into a fully integrated pharmaceutical company with over 600 employees, was a NASDAQ listed public company, and was eventually sold for $428 million in cash.*
We have proven our ability to execute; now we want to take our products to the next level.
FDA cleared Ortek-ECD® —
- An FDA Cleared Class II Medical Device
- Patented in 20 countries
- Detects early biting surface tooth decay that X-rays often miss
- Provides a digital score based on decay progression into the dentin
- Does not utilize radiation
- Has been purchased by hundreds of dentists in the U.S.
- Named a Top 100 product by Dentistry Today
- Tooth decay is the world's most common chronic disease**
- Early detection of tooth decay spares individuals the pain and expense of advanced decay, root canals, infections and tooth loss
- The ECD is a very affordable and profitable new diagnostic tool for dental professionals
- The worldwide dental equipment market was valued at $60.5 billion in 2019 and is predicted to reach $70.8 billion by 2024***
BasicBites® —
- Contains our advanced oral microbiome technology
- Activates beneficial pH-raising oral bacteria
- Immediately neutralizes harmful sugar acids, supports remineralization and helps maintain a balanced and healthy oral pH environment
- BasicBites have over $1 million in cumulative sales
- Essential for the estimated one in four adults with dry mouth
- The global market of dry mouth products was approximately $650 million in 2020 and projected to reach $825 million in 2027****
- In 2020, the global oral care market was valued at $45 billion and is estimated to reach $53 billion by 2025*****
Robust Product Pipeline —
- BasicBites Synergy Plus™ for additional oral care, bone, cardiovascular and immunity support will be launched in Q4
- BasicBites Bedtime™ for additional oral care and sleep support will be launched soon
- Ortek has worldwide exclusive licenses for two patents that naturally rebalance the body’s skin microbiome to suppress body odor and combat drug-resistant bacteria
Please join us on our path to success as we grow and prosper by revolutionizing oral care.
Closing in 5 Days! — Invest in Ortek Today
Sources:
*https://www.bizjournals.com/southflorida/stories/2009/08/24/daily71.html
**https://www.researchgate.net/publication/272725948_Dental_Caries_The_Most_Common_Disease_Worldwide_and_Preventive_Strategies
***https://www.bccresearch.com/market-research/healthcare/dental-markets-furniture-equipment-materials-supplies.html
****https://www.researchandmarkets.com/reports/5303834/xerostomia-dry-mouth-therapeutics-global
*****https://www.globenewswire.com/news-release/2020/07/21/2064748/0/en/The-oral-care-oral-hygiene-market-is-projected-to-reach-USD-53-3-billion-by-2025-from-USD-45-8-billion-in-2020-at-a-CAGR-of-3-1.html
08.31.22
Just 6 Days Left to Invest in Ortek on StartEngine!
Just 6 Days Left to Invest in FDA Cleared Game-Changing Technology!
We hope you join us on our journey to revolutionize the multi-billion dollar oral care market!
Invest in Ortek Today
08.30.22
Ortek Expands Profitable ADA and Sjögren's Foundation Marketing Campaigns
Closing in 7 Days — Invest Today!
ECD Campaign with the American Dental Association (ADA)
Our initial test marketing campaign promoting the Ortek-ECD® with the American Dental Association (ADA) exceeded our expectations! Our ECD ads in the ADA's digital Morning Huddle newsletter were profitable and generated numerous purchases by dentists across the country. In fact, we will implement a new series of digital ads starting in September and will consider print ads in the ADA's various journals.
Early Detection of the World's Most Prevalent Chronic Disease is Now a Reality!
By utilizing breakthrough electronic conductance technology, the FDA cleared and globally patented Ortek-ECD® can immediately detect cavities that X-rays often miss – and without using radiation! The ECD's digital score also indicates the severity of decay! According to the CDC, about one-fourth of young children, half of adolescents, and more than 90% of adults have experienced tooth decay.* We firmly believe the ECD is a massive breakthrough in early cavity detection, and we have only scratched the surface!
BasicBites Campaign with The Sjögren's Foundation
Ortek has been a proud supporter of the Sjögren's Foundation for years. Sjögren's ("SHOW-grins") is a systemic autoimmune disease that affects the entire body. Today as many as four million Americans, mostly women, are living with this disease.** Just one email blast to the Foundations membership generated the purchase of approximately 500 bags of BasicBites in one week! We are starting a new marketing campaign with the Sjögren's Foundation that will include print, digital and social media strategies.
Harnessing the Oral Microbiome for Enamel Health
Many patients with Sjögren's experience severe dry mouth which can lead to a high prevalence of tooth decay. Additionally, dry mouth affects one in four adults, typically from a side effect of over 500 prescription and OTC medications,***autoimmune diseases and certain cancer treatments. BasicBites are revolutionary sugar free soft chews that contain our advanced oral microbiome technology. By activating the beneficial pH-raising bacteria discovered in dental plaque, BasicBites provide additional oral care support beyond brushing and flossing.
As you can see, Ortek is not your typical med tech crowd-funded start-up. We’ve already conquered the expensive, time consuming and risky hurdles of commercializing our products with more on the way!
Closing in Just 7 Days — Invest in Ortek Today
Sources:
*https://www.cdc.gov/oralhealth/conditions/index.html
**https://www.sjogrens.org/understanding-sjogrens/frequently-asked-questions
***https://jada.ada.org/article/S0002-8177(20)30599-7/fulltext
08.26.22
A Dentist Invested in Ortek - Learn Why
Very Early Detection of the World's Most Chronic Disease is Now a Reality!
"I invested in Ortek because the ECD is an invaluable modern-day solution for detecting early stage tooth decay that radiographs miss. I have used the ECD on hundreds of patients and I continue to marvel at the ECD's accuracy. It's affordable, fast and easy to use, and I think the ECD should be purchased by nearly every dentist."
Brian Rosen, DDS
To learn more details about Dr. Rosen's clinical experience using the ECD, please click to read the article below that he recently authored in Dentistry Today.
Closing in 11 Days - Invest in Ortek Today!
Now you can invest in FDA Cleared Game-Changing Disruptive Technology
The FDA cleared Ortek-ECD® uses next-generation electronic conductance technology to immediately and accurately detect tiny cavities on the biting surfaces of the back teeth at a very early stage - without using radiation!
The ECD not only detects cavities, but instantly indicates the severity of the decay. The biting surfaces of the back teeth are the most vulnerable to decay. X-rays often fail to detect early cavities on these surfaces.
The ECD was developed and tested at a leading U.S. dental school and demonstrated 100% sensitivity and 93% specificity in a published peer-reviewed clinical study.*
Early detection of tooth decay helps patients avoid the pain and expense of advanced tooth decay, root canals, infections and tooth loss. For dental practices, the ECD not only improves patient outcomes, but is a very affordable and profitable new diagnostic tool that has a potential ROI in days.
Let's Revolutionize Oral Care Together!
Closing in 11 Days — Invest in Ortek Today
Source:
*https://www.researchgate.net/publication/333031625_Comparison_of_the_Detection_of_Early_Occlusal_Caries_in_Extracted_Human_Permanent_Molar_Teeth_by_Electrical_Conductance_and_Biopsy_Means
The above testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.
REWARDS
10%
Stack Venture Club & Rewards!
Members get an extra 10% shares in addition to rewards below!
Venture Club
Venture Club Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
$250
$250+ | 1st Perk
Invest $250+ and receive a onetime $5 off for a single bag of BasicBites.
$1,000
$1,000+ | 2nd Perk
Invest 1,000 and receive 5% bonus shares
$2,500
$2,500+ | 3rd Perk
Invest $2,500 and receive 10% bonus shares
$5,000
$5,000+ | 4th Perk
Invest $5,000+ and receive two free bags of BasicBites and 15% bonus shares
$10,000
$10,000+ | 5th Perk
Invest $10,000 and receive four free bags of BasicBites and 20% bonus shares
JOIN THE DISCUSSION
0/2500
Donald Mader
3 years ago
My wife and I are interested in investing in this company. Have concerns about your revenue projections also will like to have more information on your past year financials, interested in investing with significant amount. Thank you in advance for this information.
Show more
3
0
James Green
3 years ago
What keeps your competition from doing exactly what you are doing?
1
0
michael kojac
3 years ago
This appears to be an amazing company with a lot of potential I rather have basic bite chews then go to the dentist every 6 months for drill baby drill
Show more
1
0
Shadi Wadi-Ramahi
3 years ago
You mention the large decrease in revenue was due to sublicense and royalty fees. Aren't those yearly royalty fees? Do you have actual revenue from direct sales or your two products are licensed?
Show more
1
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
FAQS
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
William Martin Miller
3 years ago
I chatted with someone who is extremely familiar with the dentistry industry though they specialize in the area of cosmetic dentistry, and not endodontics. Their opinion was that the Ortek early cavity detection device was certainly very innovative with its electronic conductance technology, and if became common place would be of immense benefit to patients and their health. However their positive impression was dampened by realism that the excitement is not there with dentists because they generally are not that interested in early intervention - even if the device can better identify cavities compared with the blind spots in panoramic radiography (ie. mouth x-rays). The reasons posited was dentists will end up not getting endodontic work such as crowns and root canal treatments (and other procedures) to relieve pain and to "save" your natural tooth. In other words, the big ticket items. It is regrettable, but a fact. In view of this, how can Ortek Therapeutics, Inc. get more dentists to adopt its novel and FDA approved oral care technology for benefit of the consumer? After all, it is fact too that many chronic diseases can stem from or are exacerbated by poor oral health and gum disease.
Show more
1
0